SIO scientists have mined their rare collection of marine organisms to identify, characterize and analog a proprietary, small molecule with anti-cancer properties. SAR studies have identified regions of the molecule that have yielded analogs of greatest interest. Compositions of matter and methods of use are claimed for the treatment of cancer and hyperproliferative disorders.
UC inventors have used human cancer bio-assays to identify, isolate and characterize novel compositions from marine cyanobacteria. Subsequent work with parent compounds and potent analogs has yielded compositions of matter, methods for synthesis and methods of using Apratoxins F & G to treat cancer.
While in vivo studies have not confirmed which drugs will be most useful for which cancers, studies suggest the first targets may be solid tumors, particularly colon cancer. In general, any disease or condition characterized by hyperproliferative cell growth may benefit from this therapeutic approach.
Thus far, in vivo studies with Apratoxin F have corroborated the more extensive in vivo studies with the related composition, Apratoxin A (see Luesch et al., below). Complete structures and SAR have been worked out for Apratoxins F and G. Both compositions have demonstrated solid, in vitro, toxicity against two human tumor cell lines, HCT-116 and H125. Cytotoxicity was tested in NCI H-460 human lung tumor cells and HCT-116 cells.
Worldwide rights available for pending patent application WO2011/112893.
|United States Of America||Issued Patent||8,598,313||12/03/2013||2010-216|
New Chemical Entity, NCE, composition, Natural Product, Cancer , oncology, tumor, colon cancer, hyperproliferative, hyperproliferation, therapy, therapeutic, analog, Apratoxin, cytotoxicity, SAR, structure activity, structure-activity